As discussed in the inclusion criteria, in our center, we treat patients with osteoporosis and previous fractures with teriparatide only when they present with a homogeneous trend of low bone turnover in the absence of therapies that might excessively suppress PTH. This evidence concerns the gene PTH and osteoporosis.